Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks.
Head and neck cancer is the world’s sixth most common form of the disease. If it spreads or comes back after standard treatment, patients may be offered immunotherapy and platinum chemotherapy. But if this fails, there is often little else doctors can do.
Research showed a drug called amivantamab, given as an injection, can shrink tumours in patients with recurrent or metastatic cancer who had tried immunotherapy and chemotherapy. Details were presented at the European Society for Medical Oncology conference in Berlin.
Prof Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research in London, and consultant oncologist at the Royal Marsden NHS foundation trust, said: “To see this level of benefit for patients who have endured numerous treatments is incredibly encouraging.
